Insulin Resistance and the Polycystic Ovary Syndrome Revisited: An Update on Mechanisms and Implications
Open accessThe DOI matches its Crossref record; 621 of the 628 references it cites were found in a registry or an index.
Abstract
Polycystic ovary syndrome (PCOS) is now recognized as an important metabolic as well as reproductive disorder conferring substantially increased risk for type 2 diabetes. Affected women have marked insulin resistance, independent of obesity. This article summarizes the state of the science since we last reviewed the field in the Endocrine Reviews in 1997. There is general agreement that obese women with PCOS are insulin resistant, but some groups of lean affected women may have normal insulin sensitivity. There is a post-binding defect in receptor signaling likely due to increased receptor and insulin receptor substrate-1 serine phosphorylation that selectively affects metabolic but not mitogenic pathways in classic insulin target tissues and in the ovary. Constitutive activation of serine kinases in the MAPK-ERK pathway may contribute to resistance to insulin's metabolic actions in skeletal muscle. Insulin functions as a co-gonadotropin through its cognate receptor to modulate ovarian steroidogenesis. Genetic disruption of insulin signaling in the brain has indicated that this pathway is important for ovulation and body weight regulation. These insights have been directly translated into a novel therapy for PCOS with insulin-sensitizing drugs. Furthermore, androgens contribute to insulin resistance in PCOS. PCOS may also have developmental origins due to androgen exposure at critical periods or to intrauterine growth restriction. PCOS is a complex genetic disease, and first-degree relatives have reproductive and metabolic phenotypes. Several PCOS genetic susceptibility loci have been mapped and replicated. Some of the same susceptibility genes contribute to disease risk in Chinese and European PCOS populations, suggesting that PCOS is an ancient trait.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Insulin resistance and hyperinsulinemia, either directly or indirectly, through factors such as adiposity can lead to increase circulating androgen levels (6).”
From Obstructive sleep apnea syndrome in polycystic ovary syndrome: a systematic review and meta-analysis (2025) · cites this paper as [6]
In the citing paper
“Androgen excess favors visceral fat deposition and lipid dysfunction with a vicious cycle of worsening of hyperinsulinemia and insulin resistance (6).”
From Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis (2024) · cites this paper as [6]
In the citing paper
“primarily due to hyperinsulinemia resulting from insulin resistance, which increases ovarian androgen production [162, 163].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [163]
In the citing paper
“Moreover, women who have both obesity and PCOS exhibit a greater level of insulin resistance in comparison to obese persons who do not have PCOS [53].”
In the citing paper
“Consensus is yet to be achieved in lean women with PCOS as IR is not consistently demonstrated (Diamanti-Kandarakis and Dunaif, 2012).”
From Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic–hyperinsulinaemic clamp studies (2016) · cites this paper as Diamanti-Kandarakis and Dunaif, 2012
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s062 · Cited by 13,988
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
The Wellcome Trust Case Control Consortium, Management Committee, Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D. P., McCarthy, M. I., et al. (2007) · Nature · doi:10.1038/nature05911 · Cited by 9,442
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
Finding the missing heritability of complex diseases
Manolio, T. A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., Hunter, D. J., McCarthy, M. I., Ramos, E. M., Cardon, L. R., Chakravarti, A., et al. (2009) · Nature · doi:10.1038/nature08494 · Cited by 8,336
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus
Shi, Y., & Massagué, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00432-x · Cited by 5,857
Research works printed but not linked: 5
- Achard, 1921, Le virilisme et son association à l'insuffisance glycolytique (diabète des femmes à barbe), Bull Acad Natl Med (Paris), 86, 51
- Vague, 1947, La différentiation sexuelle. Facteur determinant des formes de l'obesité, Presse Med, 55, 339
- Chereau, 1844, Mémoires pour servir à l'étude des malades ovaires
- Givens, 1992, Historical Overview of the Polycystic Ovary, 3
- Zawadzki, 1992, Diagnostic criteria for polycystic ovary syndrome; towards a rational approach, 377
Cited by
Items 201–300 of 1,006
Effect of maternal PCOS and PCOS-like phenotype on the offspring's health
Puttabyatappa, M., Cardoso, R. C., & Padmanabhan, V. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.11.030 · Cited by 85
“Disclosure statement: The authors have nothing to disclose anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript (T2DM) and cardiovascular diseases (Diamanti-Kandarakis and Dunaif, 2012, Moran et al., 2015).”
BackgroundEndometriosis and polycystic ovary syndrome are diametric disorders
Dinsdale, N. L., & Crespi, B. J. (2021) · Evolutionary Applications · doi:10.1111/eva.13244 · Cited by 90
Behavioral approaches to nutrition and eating patterns for managing type 2 diabetes: A review
Salvia, M. G., & Quatromoni, P. A. (2023) · American Journal of Medicine Open · doi:10.1016/j.ajmo.2023.100034 · Cited by 91
Zhang, D., Zhang, L., Yue, F., Zheng, Y., & Russell, R. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-0589 · Cited by 83
Baranova, A., Tran, T. P., Afendy, A., Wang, L., Shamsaddini, A., Mehta, R., Chandhoke, V., Birerdinc, A., & Younossi, Z. M. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-133 · Cited by 85
“Intuitively, one would assume insulin resistance to be always associated with obesity, but clinical evidence has revealed that it exists in both lean and obese women with PCOS [13,14].”
BackgroundThe correlation between serum AMH and HOMA-IR among PCOS phenotypes
Wiweko, B., Indra, I., Susanto, C. A., Natadisastra, M., & Hestiantoro, A. (2018) · BMC Research Notes · doi:10.1186/s13104-018-3207-y · Cited by 90
Insulin Resistance in Patients With Acromegaly
Vila, G., Jørgensen, J. O. L., Luger, A., & Stalla, G. K. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00509 · Cited by 89
Kazemi, M., Kim, J. Y., Wan, C., Xiong, J. D., Michalak, J., Xavier, I. B., Ganga, K., Tay, C. T., Grieger, J. A., Parry, S. A., et al. (2022) · Human Reproduction Update · doi:10.1093/humupd/dmac023 · Cited by 89
Associations Between Diabetes Mellitus and Neurodegenerative Diseases
Szablewski, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020542 · Cited by 91
“Hyperinsulinemia due to insulin resistance is also associated with diseases such as non-alcoholic fatty liver disease (NAFLD) [86], polycystic ovary syndrome [87,88], Alzheimer’s disease [89,90] and cardiovascular and cerebrovascular diseases [91–93].”
New biomarkers for diagnosis and management of polycystic ovary syndrome
Karakas, S. E. (2017) · Clinica Chimica Acta · doi:10.1016/j.cca.2017.06.009 · Cited by 90
Stepto, N. K., Moreno-Asso, A., McIlvenna, L. C., Walters, K. A., & Rodgers, R. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00167 · Cited by 78
Mechanisms IN endocrinology: metabolic syndrome through the female life cycle
Vryonidou, A., Paschou, S. A., Muscogiuri, G., Orio, F., & Goulis, D. G. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0275 · Cited by 88
Kheirollahi, A., Teimouri, M., Karimi, M., Vatannejad, A., Moradi, N., Borumandnia, N., & Sadeghi, A. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01410-8 · Cited by 88
The Disorders of Endometrial Receptivity in PCOS and Its Mechanisms
Jiang, N.-X., & Li, X. (2021) · Reproductive Sciences · doi:10.1007/s43032-021-00629-9 · Cited by 89
Obesity-Related Hypogonadism in Women
Eng, P. C., Phylactou, M., Qayum, A., Woods, C., Lee, H., Aziz, S., Moore, B., Miras, A. D., Comninos, A. N., Tan, T., et al. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad027 · Cited by 90
Polycystic Ovary Syndrome (PCOS): Symptoms, Causes, and Treatment
Bai, H., Ding, H., & Wang, M. (2024) · Clinical and Experimental Obstetrics & Gynecology · doi:10.31083/j.ceog5105126 · Cited by 89
Jia, L., Li, J., He, B., Jia, Y., Niu, Y., Wang, C., & Zhao, R. (2016) · Scientific Reports · doi:10.1038/srep19436 · Cited by 88
Simon, S. L., McWhirter, L., Diniz Behn, C., Bubar, K. M., Kaar, J. L., Pyle, L., Rahat, H., Garcia-Reyes, Y., Carreau, A.-M., Wright, K. P., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02385 · Cited by 87
Perspectives in polycystic ovary syndrome: From hair to eternity
Dunaif, A. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3780 · Cited by 87
“The FSHR is another highly plausible candidate gene for PCOS, given its characteristic abnormalities of folliculogenesis (10, 58).”
BackgroundInfluentialSelf-citationRichards, J. S. (2018) · Vitamins and hormones · doi:10.1016/bs.vh.2018.01.009 · Cited by 90
Jensterle, M., Kocjan, T., Kravos, N. A., Pfeifer, M., & Janez, A. (2015) · Endocrine Research · doi:10.3109/07435800.2014.966385 · Cited by 86
“IR calculated using HOMAIR score in women with PCOS and relatively low sensitivity of HOMAIR score method in detecting specific form of IR that characterizes PCOS were reported in other trails (36,37).”
MethodThe role of androgen in autophagy of granulosa cells from PCOS
Li, X., Qi, J., Zhu, Q., He, Y., Wang, Y., Lu, Y., Wu, H., & Sun, Y. W. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1540567 · Cited by 86
“Polycystic ovary syndrome (PCOS) is the most common cause of chronic anovulation infertility with the incidence of 6–8% in reproductive age women [1,2], characterized by hyperandrogenism, anovulation, insulin resistance (IR), and obesity [3].”
BackgroundRole of exercise training in polycystic ovary syndrome: a systematic review and meta-analysis
Benham, J. L., Yamamoto, J. M., Friedenreich, C. M., Rabi, D. M., & Sigal, R. J. (2018) · Clinical Obesity · doi:10.1111/cob.12258 · Cited by 85
“In PCOS, these demonstrated improvements in metabolic parameters, especially insulin resistance, may lead to an improvement in reproductive function as insulin acts as a reproductive hormone participating in ovarian steroidogenesis and in the central hormonal control of ovulation (39).”
BackgroundHuang, J., Duan, C., Jin, S., Sheng, C.-B., Wang, Y., Yue, Z., & Guo, B. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.69343 · Cited by 85
Christ, J. P., & Falcone, T. (2018) · Obesity Surgery · doi:10.1007/s11695-018-3155-6 · Cited by 85
Crisosto, N., Ladrón de Guevara, A., Echiburú, B., Maliqueo, M., Cavada, G., Codner, E., Paez, F., & Sir-Petermann, T. (2019) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.10.011 · Cited by 69
Do GLP-1 Analogs Have a Place in the Treatment of PCOS? New Insights and Promising Therapies
Szczesnowicz, A., Szeliga, A., Niwczyk, O., Bala, G., & Meczekalski, B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185915 · Cited by 83
“Insulin resistance (IR) is a hallmark of PCOS, with approximately 50–80% of PCOS patients affected [6].”
BackgroundKahal, H., Kyrou, I., Tahrani, A. A., & Randeva, H. S. (2017) · Clinical Endocrinology · doi:10.1111/cen.13392 · Cited by 70
“Insulin may act directly on the ovaries to enhance androgen production (33); reduce SHBG production from the liver with subsequent increase in bioavailable testosterone; and cause the premature arrest of follicle growth and anovulation (34).”
BackgroundPCOS during the menopausal transition and after menopause: a systematic review and meta-analysis
Millán-de-Meer, M., Luque-Ramírez, M., Nattero-Chávez, L., & Escobar-Morreale, H. F. (2023) · Human Reproduction Update · doi:10.1093/humupd/dmad015 · Cited by 82
Garg, G., Kachhawa, G., Ramot, R., Khadgawat, R., Tandon, N., Sreenivas, V, Kriplani, A., & Gupta, N. (2015) · Endocrine Connections · doi:10.1530/ec-15-0001 · Cited by 68
Skarra, D. V., Hernandez, A. M., Rivera, A. J., Anvar, A. R., & Thackray, V. G. (2017) · Endocrinology · doi:10.1210/en.2016-1898 · Cited by 83
Obesity-associated cardiovascular risk in women: hypertension and heart failure
Faulkner, J. (2021) · Clinical Science · doi:10.1042/cs20210384 · Cited by 81
Triglycerides and glucose index as an insulin resistance marker in a sample of healthy adults
Toro-Huamanchumo, C. J., Urrunaga‐Pastor, D., Guarnizo-Poma, M., Lázaro-Alcántara, H., Paico-Palacios, S., Pantoja-Torres, B., Ranilla-Seguin, V. D. C., & Benites-Zapata, V. A. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.09.010 · Cited by 80
Sun, Z., Chang, H., Wang, A., Song, J., Zhang, X., Guo, J., Leung, P. C. K., & Lian, F. (2019) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-019-0490-y · Cited by 80
He, F., & Li, Y. (2021) · Journal of Ovarian Research · doi:10.1186/s13048-021-00799-9 · Cited by 81
Gupta, M., Yadav, R., Mahey, R., Agrawal, A., Upadhyay, A. D., Malhotra, N., & Bhatla, N. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2019.1613640 · Cited by 79
“3%) correlates with previous studies varying between 44 and 70% [5].”
BackgroundMelin, J., Forslund, M., Alesi, S., Piltonen, T., Romualdi, D., Spritzer, P. M., Tay, C. T., Pena, A., Witchel, S. F., Mousa, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad465 · Cited by 78
Síndrome de ovario poliquístico en la mujer adulta
Ortiz-Flores, A. E., Luque‐Ramírez, M., & Escobar-Morreale, H. F. (2019) · Medicina Clínica · doi:10.1016/j.medcli.2018.11.019 · Cited by 77
Endocrine-metabolic dysfunction in polycystic ovary syndrome: An evolutionary perspective
Dumesic, D. A., Abbott, D. H., Sanchita, S., & Chazenbalk, G. D. (2020) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2020.02.013 · Cited by 76
“In women with PCOS, moreover, hyperinsulinemia in the presence of obesity interacts with hyperandrogenism to worsen the PCOS phenotype [1, 5, 8, 9].”
BackgroundPerspectives on polycystic ovary syndrome: Is polycystic ovary syndrome research underfunded?
Brakta, S., Lizneva, D., Mykhalchenko, K., Imam, A., Walker, W., Diamond, M. P., & Azziz, R. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01415 · Cited by 76
Tabrizi, R., Ostadmohammadi, V., Akbari, M., Lankarani, K. B., Vakili, S., Peymani, P., Karamali, M., Kolahdooz, F., & Asemi, Z. (2022) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-019-09559-0 · Cited by 76
Regidor, P., Mueller, A., Sailer, M., Santos, F. G., Rizo, J. M., & Egea, F. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010384 · Cited by 77
“In fact, hyperinsulinemia, independent of BMI, is a key contributor to PCOS pathogenesis [7,8] as it results in augmented androgen production in the adrenal cortex”
BackgroundKarimi, A., Tutunchi, H., Naeini, F., Vajdi, M., Mobasseri, M., & Najafipour, F. (2022) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13698 · Cited by 76
Cardiometabolic risks in PCOS: a review of the current state of knowledge
Kakoly, N. S., Moran, L., Teede, H. J., & Joham, A. E. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2019.1556094 · Cited by 77
“The interplay between etiologic risk factors including genetic and environmental, lifestyle and hormonal abnormalities contribute to the pathology of PCOS [1,23].”
BackgroundChen, Y., Zhang, X., An, Y., Liu, B., & Lu, M. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110697 · Cited by 76
Mei, S., Ding, J., Wang, K., Ni, Z., & Yu, J. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.876620 · Cited by 75
Patten, R. K., McIlvenna, L. C., Levinger, I., GARNHAM, A. P., Shorakae, S., Parker, A. G., McAinch, A. J., Rodgers, R. J., Hiam, D., Moreno‐Asso, A., et al. (2022) · Human Reproduction · doi:10.1093/humrep/deac047 · Cited by 77
Tee, M. K., & Miller, W. L. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.460048 · Cited by 69
“the chain of the insulin receptor (52, 53) or its substrate IRS-1 (54) appears to be involved.”
BackgroundDiVall, S. A., Herrera, D., Sklar, B., Wu, S., Wondisford, F., Radovick, S., & Wolfe, A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0119995 · Cited by 67
“levels are not lower in the setting of lower LH, likely because of enhanced steroidogenesis due to insulin action on the ovary [2, 3].”
BackgroundMANAGEMENT OF ENDOCRINE DISEASE: Morbidity in polycystic ovary syndrome
Glintborg, D., & Andersen, M. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0373 · Cited by 63
Liu, S., Mo, M., Xiao, S., Li, L., Hu, X., Hong, L., Wang, L., Lian, R., Huang, C., Zeng, Y., et al. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.575337 · Cited by 75
Günalan, E., Yaba, A., & Yılmaz, B. (2018) · Journal of the Turkish-German Gynecological Association · doi:10.4274/jtgga.2018.0077 · Cited by 74
“has a central role in the pathogenesis of PCOS (12).”
BackgroundKahal, H., Aburima, A., Ungvari, T., Rigby, A. S., Coady, A. M., Vince, R. V., Ajjan, R. A., Kilpatrick, E. S., Naseem, K. M., & Atkin, S. L. (2015) · BMC Endocrine Disorders · doi:10.1186/s12902-015-0005-6 · Cited by 74
“It is worth noting that HOMA-β, although simple and commonly used, has many limitations including the use of a fasting parameter of β-cell function, which reflects basal rather than glucose-stimulated insulin secretion, and is also affected by alterations in insulin clearance [45-47].”
BackgroundLiu, X., Sun, C., Zou, K., Li, C., Chen, X., Gu, H., Zh, Z., Yang, Z., Tu, Y., Qin, N., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103058 · Cited by 74
“Potential mechanisms associated with PCOS development have been studied [33-35]; however, because of the heterogeneous and comprehensive nature of the endocrine disorders associated with PCOS, the pathogenesis has not yet been fully explained by any reported mechanism.”
BackgroundAndrogen dysfunction in non-alcoholic fatty liver disease: Role of sex hormone binding globulin
Song, M. J., & Choi, J. Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1053709 · Cited by 74
Questioning PCOS phenotypes for reclassification and tailored therapy
Myers, S. H., Russo, M., Dinicola, S., Forte, G., & Unfer, V. (2023) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2023.08.005 · Cited by 74
de Wilde, M. A., Veltman-Verhulst, S. M., Goverde, A. J., Lambalk, C. B., Laven, J. S. E., Franx, A., Koster, M. P. H., Eijkemans, M. J. C., & Fauser, B. C. J. M. (2014) · Human Reproduction · doi:10.1093/humrep/deu077 · Cited by 63
“Associated features include obesity, impaired glucose tolerance, dyslipidaemia and metabolic dysfunction (Moran et al., 2010; Wild et al., 2011; Diamanti-Kandarakis and Dunaif, 2012).”
BackgroundChang, C. L., Huang, S. Y., Soong, Y. K., Cheng, P. J., Wang, C.-J., & Liang, I. T. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1180 · Cited by 65
Tao, T., Zhang, Y., Zhu, Y.-C., Fu, J.-R., Wang, Y.-Y., Cai, J., Ma, J.-Y., Xu, Y., Gao, Y.-N., Sun, Y., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa692 · Cited by 62
Zhang, J., Xing, C., Cheng, X., & He, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1003238 · Cited by 73
Ectopic fat: the true culprit linking obesity and cardiovascular disease?
Morelli, M., Gaggini, M., Daniele, G., Marraccini, P., Sicari, R., & Gastaldelli, A. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-04-0285 · Cited by 68
“Metabolic abnormalities can be observed also in non-obese subjects with ectopic fat accumulation, such as non-alcoholic fatty liver disease (NAFLD), characterised by hepatic steatosis (44) or in lean women with poly- cystic ovary syndrome (PCOS) (45).”
BackgroundPersonality and Psychiatric Disorders in Women Affected by Polycystic Ovary Syndrome
Scaruffi, E., Gambineri, A., Cattaneo, S., Turra, J., Vettor, R., & Mioni, R. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00185 · Cited by 63
Women-specific predictors of cardiovascular disease risk - new paradigms
Maffei, S., Guiducci, L., Cugusi, L., Dessalvi, C. C., Deidda, M., Gallina, S., Sciomer, S., Gastaldelli, A., & Kaski, J. C. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.02.005 · Cited by 78
Polycystic Ovarian Syndrome: Long-Term Health Consequences
Zore, T., Joshi, N., Lizneva, D., & Azziz, R. (2017) · Seminars in Reproductive Medicine · doi:10.1055/s-0037-1603096 · Cited by 72
Ujvari, D., Hulchiy, M., Calaby, A., Nybacka, A., Bystrom, B., & Hirschberg, A. L. (2014) · Human Reproduction · doi:10.1093/humrep/deu114 · Cited by 72
“Several investigations on cultured skin fibroblasts, as well as on fat and skeletal muscle, the primary targets of insulin action, indicate impairment of metabolic signaling involving serine phosphorylation of the insulin receptor and insulin receptor substrate-1 (IRS1) (Dunaif et al., 2001; Li et al., 2002; Corbould…”
BackgroundResultInfluentialApproach to Investigation of Hyperandrogenism in a Postmenopausal Woman
Hirschberg, A. L. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac673 · Cited by 77
Insulin resistance, metabolic syndrome and polycystic ovaries: an intriguing conundrum
Prosperi, S., & Chiarelli, F. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1669716 · Cited by 72
Sarkar, M., Wellons, M., Cedars, M. I., VanWagner, L., Gunderson, E. P., Ajmera, V., Torchen, L., Siscovick, D., Carr, J. J., Terry, J. G., et al. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2017.44 · Cited by 67
Inositols’ Importance in the Improvement of the Endocrine–Metabolic Profile in PCOS
Wojciechowska, A., Osowski, A., Jóźwik, M., Górecki, R., Rynkiewicz, A., & Wojtkiewicz, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225787 · Cited by 59
“Insulin resistance has been associated with the occurrence of many cardiometabolic disorders, such as obesity, impaired glucose tolerance, type 2 DM, dyslipidemia, hypertension, metabolic syndrome, and cardiovascular disease [32].”
BackgroundTosi, F., Di Sarra, D., Kaufman, J.-M., Bonin, C., Moretta, R., Bonora, E., Zanolin, E., & Moghetti, P. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2786 · Cited by 70
Zhang, S., Tu, H., Yao, J., Le, J., Jiang, Z., Tang, Q., Zhang, R., Huo, P., & Lei, X. (2020) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-020-00613-z · Cited by 70
“However, there is relative deficit in FSH secretion, which often results in impaired and arrested follicular development and reduced aromatase activity, thereby resulting in ovarian follicular atresia and hyperandrogenemia in PCOS women [3].”
BackgroundHeilmann‐Heimbach, S., Hochfeld, L. M., Henne, S. K., & Nöthen, M. M. (2020) · Experimental Dermatology · doi:10.1111/exd.14130 · Cited by 70
Gut microbiota as the critical correlation of polycystic ovary syndrome and type 2 diabetes mellitus
Duan, L., An, X., Zhang, Y., Jin, D., Zhao, S., Zhou, R., Duan, Y., Zhang, Y., Liu, X., & Lian, F. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112094 · Cited by 70
Hyperandrogenism in Women with Polycystic Ovarian Syndrome: Pathophysiology and Controversies
Kanbour, S., & Dobs, A. S. (2022) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2021.0020 · Cited by 70
“25 Hyperinsulinemia stimulates the hypothalamic–pituitary–adrenal axis both centrally 32 and peripherally, 32,33 leading to increased adrenal androgen production.”
Probiotics and Polycystic Ovary Syndrome: A Perspective for Management in Adolescents with Obesity
Calcaterra, V., Rossi, V., Massini, G., Casini, F., Zuccotti, G., & Fabiano, V. (2023) · Nutrients · doi:10.3390/nu15143144 · Cited by 70
Shao, R., Li, X., Feng, Y., Lin, J.-F., & Billig, H. (2014) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-33-41 · Cited by 72
“In the clinic, insulin resistance and hyperinsulinemia appear to be the major contributors to the pathophysiology of PCOS in women [13,15,63] regardless of whether or not the women are also obese [13,15,64].”
BackgroundInsulin Metabolism in Polycystic Ovary Syndrome: Secretion, Signaling, and Clearance
Herman, R., Sikonja, J., Jensterle, M., Janez, A., & Dolzan, V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043140 · Cited by 69
REPRODUCTION SYMPOSIUM: Developmental programming of reproductive and metabolic health1,2
Padmanabhan, V., & Veiga-Lopez, A. (2014) · Journal of Animal Science · doi:10.2527/jas.2014-7637 · Cited by 63
“Women with PCOS are characterized by oligo- / anovulation, hyperandrogenism, polycystic ovaries, LH hypersecretion and reduced fecundity with most manifesting insulin resistance (Diamanti-Kandarakis and Dunaif, 2012).”
High-fat diets exaggerate endocrine and metabolic phenotypes in a rat model of DHEA-induced PCOS
Zhang, H., Yi, M., Zhang, Y., Jin, H., Zhang, W., Yang, J., Yan, L., Li, R., Zhao, Y., & Qiao, J. (2016) · Reproduction · doi:10.1530/rep-15-0542 · Cited by 69
Esmaeilinezhad, Z., Barati‐Boldaji, R., Brett, N. R., de Zepetnek, J. O. T., Bellissimo, N., Babajafari, S., & Sohrabi, Z. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01139-x · Cited by 69
Resistance exercise impacts lean muscle mass in women with polycystic ovary syndrome
KOGURE, G. S., MIRANDA-FURTADO, C. L., SILVA, R. C., MELO, A. S., FERRIANI, R. A., DE SÁ, M. F. S., & REIS, R. M. D. (2016) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000000822 · Cited by 68
“The PCOS group (n = 45) was classified using the Rotterdam consensus (43), which defines four distinct phenotypes that may differ in the metabolic risk profile: 1) anovulation + hyperandrogenism; 2) anovulation + polycystic ovaries; 3) hyperandrogenism + polycystic ovaries; and 4) anovulation + hyperandrogenism + poly…”
MethodAustregésilo de Athayde De Hollanda Morais, B., Martins Prizão, V., de Moura de Souza, M., Ximenes Mendes, B., Rodrigues Defante, M. L., Cosendey Martins, O., & Rodrigues, A. M. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108834 · Cited by 68
Exercise and insulin resistance in PCOS: muscle insulin signalling and fibrosis
Stepto, N. K., Hiam, D., Gibson‐Helm, M. E., Cassar, S., Harrison, C. L., Hutchison, S. K., Joham, A. E., Canny, B. J., Moreno‐Asso, A., Strauss, B. J., et al. (2020) · Endocrine Connections · doi:10.1530/ec-19-0551 · Cited by 69
“Our data allowed us to explore the hypothesis of Diamanti-Kandarakis and Dunaif (13) where there may be a PCOS-specific serine kinase targeting IRS1/2. mTOR could be this kinase (38, 39), however, our in vivo data contrast with this hypothesis as no insulin-stimulated change was detected in any group.”
BackgroundResultInfluentialMetabolic syndrome and its components in different phenotypes of polycystic ovary syndrome
Krentowska, A., & Kowalska, I. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3464 · Cited by 71
“Insulin resistance is believed to be a constitutional feature of PCOS, especially in genetically predisposed women, often present even in lean patients.(2,78) Intrinsic abnormalities in insulin signalling, independent of other factors, have been observed in skeletal muscle and adipose tissue of PCOS patients.”
BackgroundInfluentialUnfer, V., Kandaraki, E., Pkhaladze, L., Roseff, S., Vazquez-Levin, M. H., Laganà, A. S., Chan, S. Y., Yap‐Garcia, M. I. M., Greene, N. D. E., Soulage, C. O., et al. (2024) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2024.100159 · Cited by 70
Cardoso, R. C., Veiga-Lopez, A., Moeller, J., Beckett, E., Pease, A., Keller, E., Madrigal, V., Chazenbalk, G., Dumesic, D., & Padmanabhan, V. (2016) · Endocrinology · doi:10.1210/en.2015-1565 · Cited by 67
Ezeh, U., Ezeh, C., Pisarska, M. D., & Azziz, R. (2021) · Fertility and Sterility · doi:10.1016/j.fertnstert.2020.12.015 · Cited by 50
Glucose intolerance states in women with the polycystic ovary syndrome
Pasquali, R., & Gambineri, A. (2013) · Journal of Endocrinological Investigation · doi:10.1007/bf03346757 · Cited by 67
“A recent case-control study of candidate genes in the insulin metabolic signaling pathway did replicate an association between PCOS and a single nucleotide polymorphism (SNP) in the insulin receptor gene (4).”
InfluentialBelani, M., Deo, A., Shah, P., Banker, M., Singal, P. K., & Gupta, S. S. (2018) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2018.01.008 · Cited by 67
“Polycystic ovary after exclusion of disorders of pituitary or the adrenal that could present in a manner similar to PCOS [2].”
Cioana, M., Deng, J., Nadarajah, A., Hou, M., Qiu, Y., Chen, S. S. J., Rivas, A., Banfield, L., Alfaraidi, H., Alotaibi, A., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.47454 · Cited by 52
A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries
Niafar, M., Pourafkari, L., Porhomayon, J., & Nader, N. (2016) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-015-3976-7 · Cited by 66
“The role of obesity, IR, and hyperinsulinemia in the development of PCOS has been thoroughly explored, and it is generally accepted to play an important role in the molecular mechanisms implicated in the androgenic hypersecretion typical of this pathology [7].”
BackgroundMachado, V., Escalda, C., Proença, L., Mendes, J. J., & Botelho, J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061961 · Cited by 67
DNA methylation in polycystic ovary syndrome: Emerging evidence and challenges
Liu, Y., Qin, Y. M., Wu, B., Peng, H., Li, M., Luo, H., & Liu, L. L. (2022) · Reproductive Toxicology · doi:10.1016/j.reprotox.2022.04.010 · Cited by 66
Vasukova, E. A., Zaikova, E. K., Kalinina, O., Gorelova, I. V., Pyanova, I., Bogatyreva, E., Vasilieva, E. Y., Grineva, E. N., & Popova, P. (2023) · Biomedicines · doi:10.3390/biomedicines11102791 · Cited by 67
“Insulin and luteinizing hormone (LH) act synergistically on theca cells, stimulating ovarian androgen production [3].”
BackgroundSabag, A., Patten, R. K., Moreno‐Asso, A., Colombo, G. E., Bouzo, X. D., Moran, L., Harrison, C. L., Kazemi, M., Mousa, A., Tay, C. T., et al. (2024) · Journal of science and medicine in sport · doi:10.1016/j.jsams.2024.05.015 · Cited by 67
Phy Ali M, J. L. (2015) · Journal of Obesity & Weight Loss Therapy · doi:10.4172/2165-7904.1000259 · Cited by 53
“Insulin is the primary hormonal mediator of energy storage [7], and while hyperinsulinemia is common in PCOS, it is unclear whether it is due to excessive insulin secretion, decreased insulin clearance, or both [8].”
BackgroundDiamanti-Kandarakis, E., Papalou, O., Kandaraki, E. A., & Kassi, G. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0616 · Cited by 55
Self-citationCholesterol cholelithiasis: part of a systemic metabolic disease, prone to primary prevention
Ciaula, A. D., Wang, D. Q. ‐., & Portincasa, P. (2018) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1549988 · Cited by 67
Cardiometabolic Risk in PCOS: More than a Reproductive Disorder
Torchen, L. C. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0956-2 · Cited by 65
Early trophoblast invasion and placentation in women with different PCOS phenotypes
Palomba, S., Falbo, A., Chiossi, G., Tolino, A., Tucci, L., La Sala, G. B., & Zullo, F. (2014) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2014.04.010 · Cited by 60
“In addition, new research seems to clarify that insulin-resistance and metabolic aberrations are not absolute prerequisites of the syndrome and vary significantly among phenotypes and among subjects with the same phenotype (Diamanti-Kandarakis and Dunaif, 2012).”
Background
Metadata
- Authors
- Diamanti-Kandarakis, E., & Dunaif, A.
- Affiliations
- Medical School, University of Athens (E.D.-K.), Athens GR-14578, Greece
- Northwestern University (US)
- ORCID
- Dunaif, Andrea
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2012-10-12
- Volume
- 33
- Issue
- 6
- Pages
- 981-1030
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC5393155
- OpenAlex
- W1967263394
- Semantic Scholar
- b2b7fa060bf61f261edf17bef51cbbbd222742e0
- Cited by
- 1,947
- References
- 628
- Citations by year
- 2026: 183 · 2025: 178 · 2024: 182 · 2023: 221 · 2022: 191 · 2021: 184 · 2020: 136 · 2019: 140 · 2018: 108 · 2017: 97 · 2016: 96 · 2015: 92 · 2014: 91 · 2013: 43 · 2012: 4
- FWCI
- 9.98
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK073411)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (P50HD044405, R01HD057223, U54HD034449)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Keywords
- polycystic ovary syndrome, insulin resistance, insulin receptor signaling, MAPK/ERK pathway, skeletal muscle insulin sensitivity, ovarian steroidogenesis, ovulation, brain insulin signaling, body weight regulation, insulin-sensitizing drugs, androgens, developmental origins of health and disease, fetal growth restriction, genetic susceptibility loci, type 2 diabetes risk, lean PCOS
- MeSH terms
- Female, Humans, Insulin Resistance, Phenotype, Polycystic Ovary Syndrome, Reproduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.